Trial Profile
A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary) ; Aluminium hydroxide; Hepatitis B vaccine recombinant
- Indications Hepatitis B; Hepatitis E
- Focus Registrational; Therapeutic Use
- 09 Jul 2020 Status changed from active, no longer recruiting to completed.
- 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verifiedJan 2016 ).
- 23 Aug 2010 Primary endpoint 'Vaccine protective efficacy' has been met.